about
Highlights lecture EANM 2015: the search for nuclear medicine's superheroesErythroid 5-aminolevulinate synthase, ferrochelatase and DMT1 expression in erythroid progenitors: differential pathways for erythropoietin and iron-dependent regulationUltra-low activities of a common radioisotope for permission-free tracking of a drosophilid fly in its natural habitat.[(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosisBone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals.Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative.Developing Targeted Hybrid Imaging Probes by Chelator ScaffoldingComparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607.The influence of chelator on the pharmacokinetics of 99mTc-labelled peptides.An iron-mimicking, Trojan horse-entering fungi--has the time come for molecular imaging of fungal infections?Peptide targeted imaging of cancer.Novel Bifunctional Cyclic Chelator for (89)Zr Labeling-Radiolabeling and Targeting Properties of RGD ConjugatesPreclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging.Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue.Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.Selected ⁶⁸Ga-siderophores versus ⁶⁸Ga-colloid and ⁶⁸Ga-citrate: biodistribution and small animal imaging in miceIn Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores.Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patientsComparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft Tumors.Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles.Siderophores for molecular imaging applications.Feasibility and availability of ⁶⁸Ga-labelled peptides.Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: a concise overview and practical guidance for a risk-based approach.Targeting Gastrointestinal Stromal Tumor with 68Ga-Labeled Peptides: An In Vitro Study on Gastrointestinal Stromal Tumor-Cell Lines.[(68)Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation.Image fusion analysis of 99m Tc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland.[⁶⁸Ga]NS₃-RGD and [⁶⁸Ga] Oxo-DO3A-RGD for imaging α(v)β₃ integrin expression: synthesis, evaluation, and comparison.Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies.Targeting properties of peptide-modified radiolabeled liposomal nanoparticles.[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.Novel 99mTc '4 + 1' peptide conjugates: tuning the biodistribution by variation of coligands.Radiopharmacy: regulations and legislations in relation to human applications.Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours.In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys).[99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis.99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide.
P50
Q26745705-CD66B8EB-ADB7-4573-9A4D-D24D93D76B91Q28215919-4831A259-F35F-4F47-AE1B-F8F820D5D2B6Q30827547-575955F4-3C98-469A-A302-3F1DC681101DQ31095114-AA4EFDE7-B398-4389-86D5-9B8D5868F737Q33484071-372B6042-0990-49B3-968F-0BE07F0BB2B5Q33788353-730566E6-1A36-4958-895D-21202046995FQ33818847-A9E939A2-9123-4E03-8E9A-26ACB8991F35Q33827092-FC0CA026-52D0-4C0B-ABA1-4AB683B2AAA5Q33884461-5AFB9710-A509-42CF-89F7-83E6726CECEAQ34755194-E72D28A6-DB97-40D3-BCAB-1DBFB5122E28Q35551518-12CDE1DD-B14C-4FB6-A99F-28A2896C5523Q35589625-E41C9B81-6D2D-44D1-A6AD-560D9FFD5884Q35676322-7EB83B45-4906-4049-BC18-E7C17FF5B542Q36013562-EDF653F2-788D-4901-9680-3BF326B4D60BQ36373488-8E5C099A-32C0-44A2-91BB-71AA69AD7AA2Q36440766-3DA17CE4-42F3-4C29-AAC8-73B42A819229Q36755148-26946C10-7E86-4E69-B5A0-E04126760446Q36832801-E35752B5-90F4-41F2-8870-BA44C180A83EQ36909826-8DA163EA-60F3-462A-B55E-F597F07F360AQ37103342-C03DB973-E8C8-4850-90FE-5B13E9809202Q37230541-0DB74B51-C674-4DE8-8465-A3AA9DA2D1ADQ37390746-4CF9C104-FD03-425C-A7C1-8C59738D7BD6Q37609134-75AFE804-2C10-4305-97B9-3472093FED4FQ37990396-DF08EB12-CA80-4699-B1DF-7D09142EE659Q38342316-66477C4C-70E3-4E43-BC77-7243344F8C79Q38740239-3354B273-2335-4EBC-9662-68397858C7B3Q38933775-D8FA9160-D9C9-4F0D-BD71-313FD6A6479BQ39220175-60E4300B-703D-4E04-A847-EECD29F3DB8FQ39252884-5F4B49B6-9643-4876-95F0-5DC469E31D83Q39512185-7FDF6A90-11FC-4558-B369-DAEF6EF0CD1FQ39529811-D10F9972-0E5A-4878-9D06-C6022DE4846BQ39559499-429D7654-80F8-4D70-9EC0-FE506A3829C4Q39689622-286EFACE-93E4-4674-A9F0-000DF4529516Q39734320-7EF69D3F-2AC2-42C1-83D3-CD601CFF734AQ39944711-B47B6BDC-B114-41BC-9ACA-ADB1FD72A3ABQ40156559-0163A858-A835-48F4-BAAB-2AE1D63B429CQ40204297-93F9B94C-A2B3-4B03-934B-DA57F3F5D192Q40518968-D6CAE0F7-4ACC-4691-8EC9-0081712F94E1Q40533491-6A65ABEE-5982-49C3-82A2-BB269403C99CQ40951810-CB6BFE4C-8F3C-4861-8E71-4E3C9233B2C5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Clemens Decristoforo
@ast
Clemens Decristoforo
@en
Clemens Decristoforo
@es
Clemens Decristoforo
@nl
Clemens Decristoforo
@sl
type
label
Clemens Decristoforo
@ast
Clemens Decristoforo
@en
Clemens Decristoforo
@es
Clemens Decristoforo
@nl
Clemens Decristoforo
@sl
altLabel
C Decristoforo
@en
prefLabel
Clemens Decristoforo
@ast
Clemens Decristoforo
@en
Clemens Decristoforo
@es
Clemens Decristoforo
@nl
Clemens Decristoforo
@sl
P214
P106
P108
P21
P214
P2798
P31
P496
0000-0003-0566-4036
P735
P7859
viaf-313518810